SPRX Spear Alpha ETF

SpectRx, Inc. (OTCBB: SPRX) today announced the immediate availability of the new SimpleChoice(R) twist and twist Pro insulin pump infusion sets with 5 mm catheters. The new products were introduced at the American Association of Diabetes Educators (AADE) 2006 annual meeting in Los Angeles. The less invasive catheters are the shortest on the market and are designed for ease of insertion and for a more comfortable wearing experience for people with diabetes who use insulin pumps. The twist product line also features the only 360-degree rotating design on the market for maximum movement. "Now for the first time, all pump users have an opportunity to improve the quality of their pump wearing experience by switching to the new, less invasive, SimpleChoice twist and twist Pro infusion sets with 360-degree rotation," said Bill Arthur, SpectRx, Inc. president and chief operating officer. "The freedom of movement provided by the 360-degree rotating design, combined with the shortest catheter on the market, makes the twist the infusion set product for pump wearers seeking comfort and mobility. The set should also increase the appeal of our SimpleChoice product line and enhance our efforts to seek a strategic partner to help grow our insulin-delivery business." The SimpleChoice(R) twist Pro is for use with Medtronic(R) Paradigm brand insulin pumps. The SimpleChoice(R) twist is for use with all other Medtronic(R) pumps as well as all makes of Deltec(R), Animas(R), and Disetronic(R) insulin pumps. Visit www.mysimplechoice.com, or call 877-773-2879 for information on where to buy the new shorter SimpleChoice(R) twist and twist Pro. Insulin infusion sets are for use with insulin pumps worn by people with diabetes to help control their glucose levels. The disposable infusion sets are changed about every three days. Catheters are the small tubing that delivers insulin under the skin. More than 13 million Americans have been diagnosed with diabetes. About SpectRx, Inc. SpectRx, Inc. (OTCBB: SPRX) is a diabetes management company developing and providing innovative solutions for insulin delivery and glucose monitoring. SpectRx markets the SimpleChoice(R) line of innovative diabetes management products, which include insulin pump disposable supplies. SpectRx also plans to develop a consumer device for continuous glucose monitoring. The company is commercializing its non-invasive cervical cancer detection technology through its subsidiary Guided Therapeutics, Inc., which SpectRx intends to separately finance. For more information, visit SpectRx's web sites at spectrx.com, mysimplechoice.com and guidedtherapeutics.com. Trademarks are owned by their respective companies. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from SpectRx's actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in SpectRx's reports filed with the SEC, including SpectRx's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005, as amended, and subsequent quarterly reports.